The company attributed the increase to financial reserves and a $174 million shift in its stock value, according to the report.
The recall for its Rejuvenate and ABG II modular-neck hip devices began in June of 2012 because of a risk for metal corrosion.
More Articles on Devices:
AxoGen to Present Hand Graft Clinical Results at Hand Surgery Conference
GE Capital Invests $21.5M for Amedica Spine Device Development
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in December
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
